Mobile Health Technology to Enhance Abstinence in Smokers With Schizophrenia

Completed · Phase 4

Conditions studied: Schizophrenia, Cigarette Smoking

In brief

This study is designed to evaluate if a treatment the investigators call iCOMMIT is effective at helping smokers with schizophrenia stop smoking. iCOMMIT is a smoking cessation treatment that combines mobile technology with behavioral strategies, counseling, and medications.

Key facts

Study ID

NCT02420015

Run by

Duke University

People needed

35

Starts

2017-03-27

Expected to finish

2019-01-24

Last updated by the study team

2019-07-10

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Currently smoke at least ten cigarettes a day
• Have been smoking for at least one year
• Meet criteria for schizophrenia, schizoaffective disorder, or another psychotic disorder based on structured clinical interview
• Can speak and write fluent conversational English
• Are between 18 and 70 years of age
• Are willing to make a smoking cessation attempt
• Score 26 or higher on the Montreal Cognitive Assessment

You may not qualify if…

• Have a history of myocardial infarction in the past 6 months
• Have a contraindication to NRT with no medical clearance from the primary care provider or study physician
• Use and unwillingness to stop use of other forms of nicotine such as cigars, pipes, or chewing tobacco
• Are pregnant
• Meet criteria for a current manic episode based on structured clinical interview
• Are currently enrolled in another smoking cessation trial
• Are currently imprisoned or in psychiatric hospitalization

Where it is running

• Duke University Medical Center — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.